The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 42)
Therapeutic Pipeline Program, 2016
Highly Selective M1 Muscarinic Receptor Positive Allosteric Modulators for the Treatment of Parkinson's Dementia
Up to 80% of individuals with Parkinson's develop Parkinson's disease dementia (PDD), which is characterized by a progressive loss of memory and a decline in cognitive function. Available drugs approved to treat PDD can lessen the extent of cognitive decline caused by loss of activity in cholinergic brain circuits (chemical messenger system) to a limit...
Improved Biomarkers and Clinical Outcome Measures, 2016
There is a great need to identify Parkinson's disease (PD) in its earliest stages when interventions may prevent or slow neural degeneration. Given that the earliest brain pathology of PD occurs outside of the motor system, namely in the olfactory bulbs (brain regions that detect smell) and the brainstem (brain region that controls involuntary functions), we are probing the functi...
Access to Data and Biospecimens, 2016
This project aims to find biomarkers for the diagnosis and prognosis of Parkinson's disease (PD). Levels of alpha-synuclein, a protein associated with the pathogenic mechanism of PD, are determined using a tailored-designed assay (analytic test), which is based on the biochemical property of how alpha-synuclein binds lipids (fat). Total and specific pathogenic forms of alpha-synucl...
Researchers: Ronit Sharon, PhD
Research Grant, 2016
Multi-center Study of EEG Biomarkers for Alpha-synucleinopathy Diagnosis and Prognosis Decision Support Tools Using Machine Learning
Promising Outcomes of Original Grant:
In our original study, the aim was to develop computational tools based on signal processing and machine learning for the diagnosis and prediction of Parkinson's Disease (PD) and related diseases based on electroencephalogram (measures electrical activity in the brain; EEG) data in pre-symptomatic individuals. We successfully classified individuals with REM beh...
Improved Biomarkers and Clinical Outcome Measures, 2015
Developing Progression Markers of Parkinson's Disease with Multimodal Structural MRI of Substantia Nigra and Locus Coeruleus
Substantia nigra pars compacta (SNpc) and locus coeruleus (LC) are key brain areas involved in Parkinson's disease. The loss of important chemicals (dopamine and norepinephrine) made by cells in these areas leads to many of the symptoms of Parkinson's disease. Our group develops and uses magnetic resonance imaging (MRI) techniques that can measure changes in these brain areas. By s...
Researchers: Xiaoping Philip Hu, PhD